Novartis Remibrutinib Shows Positive Results in Chronic Inducible Urticaria Trial
Novartis announced positive topline results from its Phase III RemIND trial of remibrutinib in chronic inducible urticaria, meeting the primary endpoint for the three most prevalent types of the condition with significantly higher complete response rates versus placebo.